Fardis Maria 4
4 · CRISPR Therapeutics AG · Filed Jun 10, 2022
Insider Transaction Report
Form 4
Fardis Maria
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-06-09+24,000→ 24,000 totalExercise: $71.70Exp: 2032-06-09→ Common Shares (24,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 9, 2022 with respect to 24,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments.